Overall, current data support a favorable benefitrisk profile despite persistent precautionary carcinogenicity warnings
Results have not been independently verified and may vary from person to person
Henry Meds did not respond to a request for comment.) Jim Bertel, a 41-year-old who lives in Colorado and credits tirzepatide for changing his life, was also able to stockpile his compounded GLP-1 medication before his provider stopped selling it
The data suggests it may occur, but with how rare these issues are, I would say the benefits generally should outweigh vision risks
281 As approved by the FDA in 2018 for the treatment of ATTR-PN, Inotersen requires regular safety monitoring for potential adverse events, particularly thrombocytopenia and glomerulonephritis
The study is a retrospective review of the electronic medical records (EMRs) of patients in the Mayo Clinic Health System using semaglutide for the treatment of people diagnosed overweight or obese (BMI greater than 27 kg/m2) between January 1, 2021, and March 31, 2023
